



Kringle
Pharma

Press release

15 October 2025

Kringle Pharma Launches U.S. Subsidiary to Drive Global Growth

Osaka, Japan – Kringle Pharma, Inc. ("KRINGLE"), a late-stage clinical biopharmaceutical company specializing in HGF protein therapeutics for rare and intractable diseases, is pleased to announce the formation of a wholly owned subsidiary in the United States, named Kringle Pharma USA, Inc. This strategic move aims to expand our global presence and speed up the development of our leading program targeting acute spinal cord injury in the U.S., the world's largest pharmaceutical market.

Leadership Appointment

The new subsidiary will be headquartered in Georgia and led by Mr. Matt Vogelhuber, who has over 30 years of experience in the global life sciences industry. Mr. Vogelhuber's appointment as President highlights our commitment to excellence and innovation in advancing our therapeutic projects. He previously held key roles at prominent pharmaceutical companies, including Eli Lilly and Myriad Genetics, and most recently served as CEO of fluidIQ, a startup developing respiratory devices. Mr. Vogelhuber has been a trusted business development consultant to KRINGLE for many years, making him well-qualified to lead our U.S. operations.

Strategic Vision

Kiichi Adachi, President & CEO of KRINGLE, stated, "We are excited to welcome Matt to Kringle Pharma USA, Inc. His diverse expertise and proven track record in the pharmaceutical industry make him the ideal leader for our U.S. operations. The recent orphan drug designation granted by the U.S. FDA for Oremepermin alfa, intended to treat acute spinal cord injury, highlights the urgency of our mission. Establishing a U.S. subsidiary is a crucial step toward accelerating the preparation of our Investigational New Drug (IND) application and advancing our clinical development efforts in this vital market."

About Hepatocyte Growth Factor (HGF)

HGF, originally identified as an endogenous mitogen for mature hepatocytes, has shown a wide range of biological functions, including mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities. It plays a key role in the regeneration and protection of various organs. Notably, HGF has exhibited neurotrophic effects and has been validated in animal models for its therapeutic potential in spinal cord injuries, as demonstrated by research conducted by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine. The excitement about HGF as a groundbreaking therapeutic agent for spinal cord injury continues to grow.

Meanwhile, a research team led by Professor Shigeru Hirano at the Department of Otolaryngology and Head and Neck Surgery, Kyoto Prefectural University of Medicine, has investigated the anti-fibrotic effects of HGF, showing its effectiveness in treating vocal cord scarring. HGF is also emerging as a promising therapeutic option for various fibrotic diseases.

Oremepermin alfa, the proprietary name for recombinant human hepatocyte growth factor (HGF) developed by Kringle Pharma, is a glycoprotein with a molecular weight of approximately 84,000, composed of 692 amino acids, and produced in CHO cells.



Kringle
Pharma

About Kringle Pharma, Inc. <https://www.kringle-pharma.com/en/>

Founded in December 2001, Kringle Pharma is a late-stage clinical biopharmaceutical company focused on developing innovative biologics based on HGF. Currently, Oremepermin alfa is in Phase 3 in Japan for treating acute spinal cord injury and vocal cord scarring. Kringle's mission is to improve societal and global healthcare by advancing the research, development, and commercialization of HGF-based therapies for patients with incurable diseases.

Investor and Media Contact:

Matt Vogelhuber

President, US Head of Operations

Kringle Pharma USA, Inc.

Phone: 770-570-0641

Email: mvogelhuber@kringle-pharma.com